周守宁;何玉文;谢晓鸿;周承志;
ZHOU Shouning;HE Yuwen;XIE Xiaohong;ZHOU Chengzhi;Department of Pharmacy,The First Affiliated Hospital of Guangzhou Medical University;Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University;

• 1:广州医科大学附属第一医院药学部
• 2:广州医科大学附属第一医院广州呼吸健康研究院

摘要(Abstract)：

目的探讨纳武利尤单抗致免疫性肝损伤的临床特点和防治原则。方法回顾1例非小细胞肺癌患者接受肿瘤免疫治疗过程中的病程变化,结合纳武利尤单抗的临床研究、免疫相关不良反应的诊治规范,对本案例进行分析。结果纳武利尤单抗导致了患者出现免疫性肝损伤。在停药予以对症处理后,患者预后良好。结论在抗肿瘤免疫治疗的过程中,需要防范免疫相关不良反应,保证用药安全性和有效性。
OBJECTIVE To explore the clinical characteristics and treatment principles of immune liver injury induced by nivolumab. METHODS Immune liver injury induced by nivolumab was occurred in a case with non-small cell lung cancer, which was analyzed retrospectively combining with the clinical study of nivolumab and the diagnosis and treatment norms of immune-related adverse reactions(irAEs). RESULTS The patientwas occurred immune liver injury induced by Nivolumab.After withdrawal of nivolumaband symptomatic treatment, the patientrecovered. CONCLUSION It is necessary to guard against immune-related adverse reactions during immunotherapy to ensure the safety and effectiveness of drug use.

关键词(KeyWords)： 纳武利尤单抗;非小细胞肺癌;免疫性肝损伤
nivolumab;NSCLC;immune liver injury

Abstract:

Keywords:

基金项目(Foundation): 广东省医学科学技术研究基金(A2020413)

作者(Authors): 周守宁;何玉文;谢晓鸿;周承志;
ZHOU Shouning;HE Yuwen;XIE Xiaohong;ZHOU Chengzhi;Department of Pharmacy,The First Affiliated Hospital of Guangzhou Medical University;Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University;

参考文献(References)：

• [1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
• [2] 孙雪林，周磊，胡欣.PD-1抑制剂纳武利尤单抗的药理作用与临床评价[J].中国新药杂志，2019,28(12):1445-1449.
• [3] 张红银，姚宏文，唐立帅，等.纳武利尤单抗治疗非小细胞肺癌的安全性及不良反应[J].世界最新医学信息文摘，2019,19(36):27-28.
• [4] 王绮夏，蒋翔，连敏，等.2015年欧洲肝病学会临床实践指南：自身免疫性肝炎[J].临床肝胆病杂志，2015,31(12):2000-2019.
• [5] 钟巧凤，周爱萍.免疫检查点抑制剂的不良反应及处理原则[J].中国新药杂志，2017,26(7):825-830.
• [6] Wang P F,Chen Y,Song S Y,et al.Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies:A meta-analysis[J].Front Pharmacol,2017,8:730.
• [7] Eigentler T K,Hassel J C,Berking C,et al.Diagnosis,monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J].Cancer Treat Rev,2016,45:7-18.
• [8] 王巧红，吴霞.免疫检查点抑制剂治疗中免疫相关不良反应的临床表现及处理[J].中国免疫学杂志，2017,33(4):615-620.
• [9] 于世英，姚阳.肿瘤药物相关性肝损伤防治专家共识：2014版[M].北京：中国协和医科大学出版社，2014.
• [10] 施明霞，苗琪，王绮夏，等.药物介导的自身免疫性肝炎1例[J].国际消化病杂志，2019,39(2):111-113.